RecruitingPhase 3NCT07582432
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Studying Malignant vascular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grifols Biologicals, LLC
- Intervention
- Gamunex-C, 10% Injectable Solution(drug)
- Enrollment
- 49 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (5)
- Study Site 102, St. Petersburg, Florida, United States
- Study Site 101, Fort Wayne, Indiana, United States
- Study Site 105, Westbrook, Maine, United States
- Study Site 104, Columbus, Ohio, United States
- Study Site 103, Tacoma, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07582432 on ClinicalTrials.gov